TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02831673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Description: Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
Study: NCT00796991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study: NCT06033755

Intervention type: OTHER
Group type: OTHER
Intervention: Norwegian psychomotor physiotherapy
Description: The intervention consisted predominantly of Norwegian Psychomotor Physiotherapy (NPMP) in which participants received individually tailored treatment based on the body examination and reported respiratory distress. NPMP addresses bodily tension, postural de-alignments and dysfunctional breathing patterns. The consultations also included a cognitive dimension, that is a conversation, in which thoughts and behaviours about training and competing were addressed and where participants were provided with self help measures that could improve breathing during training and competing. A rehabilitation plan for each participant was designed to limit further impairments and maintaining aerobic capacity without intensifying EILO symptoms. The intervention lasted 5 months.
Study: NCT01614678

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens with color, automated
Description: Silicone hydrogel contact lens with color manufactured via an automated process

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens with color, automated
Description: Silicone hydrogel contact lens with color manufactured via an automated process

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens with color, semi-automated
Description: Silicone hydrogel contact lens with color manufactured via a semi-automated process

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens with color, semi-automated
Description: Silicone hydrogel contact lens with color manufactured via a semi-automated process
Study: NCT00572767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextro-Amphetamin
Description: After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule.
Study: NCT05979142

Intervention type: OTHER
Intervention: community-based primary care program
Description: See group description
Study: NCT03376295

Intervention type: DRUG
Intervention: LABA and the LAMA tiotropium (LABA-TIO)
Description: combinational drug

Intervention type: DRUG
Intervention: LABA and an ICS (LABA-ICS)
Description: combinational drug
Study: NCT00618085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery practice
Description: During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy and occupational therapy
Description: Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
Study: NCT00946985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: 50, 75, 100, or 150 mg eq. monthly injection for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral risperidone
Description: 2, 4, 6, or 8 mg tabs once daily for two years
Study: NCT01775397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule
Study: NCT00651729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
Study: NCT03922113

Intervention type: OTHER
Intervention: Patient follow up
Description: Patient follow up during one month

Intervention type: OTHER
Intervention: Patient follow up
Description: Patient follow up during one month

Intervention type: OTHER
Intervention: Patient follow up
Description: Patient follow up during one month
Study: NCT00933777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of sorafenib and everolimus
Description: Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
Study: NCT02670148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulative therapy
Description: We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
Study: NCT04402255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise
Description: The key elements of Pilates during supine, prone, side-lying and standing positions will be taught. These key elements are: breathing (diaphragmatic), focusing (neutral position), rib cage placement, shoulder placement, head and neck placement (neutral position). Then, Pilates based 'mat' exercises will be performed by the physiotherapist in the clinic for 8 weeks, 2 days / week, 16 sessions. Each session will be programmed to be 45 minutes. During all exercises, including warm-up and cooling, patients will be asked to provide key elements and protect them during movements. Depending on the condition of the patients, the exercises will be advanced from easy to difficult.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise
Description: The key elements of Pilates during supine, prone, side-lying and standing positions will be taught. These key elements are: breathing (diaphragmatic), focusing (neutral position), rib cage placement, shoulder placement, head and neck placement (neutral position). Then, Pilates based 'mat' exercises will be performed by the physiotherapist in the clinic for 8 weeks, 2 days / week, 16 sessions. Each session will be programmed to be 45 minutes. During all exercises, including warm-up and cooling, patients will be asked to provide key elements and protect them during movements. Depending on the condition of the patients, the exercises will be advanced from easy to difficult.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pilates exercise
Description: The key elements of Pilates during supine, prone, side-lying and standing positions will be taught. These key elements are: breathing (diaphragmatic), focusing (neutral position), rib cage placement, shoulder placement, head and neck placement (neutral position). Then, Pilates based 'mat' exercises will be performed by the physiotherapist in the clinic for 8 weeks, 2 days / week, 16 sessions. Each session will be programmed to be 45 minutes. During all exercises, including warm-up and cooling, patients will be asked to provide key elements and protect them during movements. Depending on the condition of the patients, the exercises will be advanced from easy to difficult.
Study: NCT02831673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Description: Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
Study: NCT03047980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Low dose oral sirolimus
Study: NCT02364128

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Decider Guider: Weight Loss
Description: Decision aid tool about weight loss treatment
Study: NCT03022773

Intervention type: OTHER
Group type: OTHER
Intervention: Carotenoid measurements
Description: Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.~Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.~Carotenoid measurements in the blood are obtained through routine venipuncture.
Study: NCT00874120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg
Description: Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken twice daily (12 hours apart) for 7 days.
Study: NCT02187952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral feeding intervention
Description: Behavioral feeding intervention will include escape extinction.
Study: NCT03331809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-handed jaw thrust
Description: The assistant applied two-handed jaw thrust when intubating with double-lumen tube endotracheal tube.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intubation
Description: The attending anesthesiologist provided intubation with double-lumen tube endotracheal tube without two-handed jaw thrust.
Study: NCT04395261

Intervention type: DIAGNOSTIC_TEST
Intervention: Wideband Tympanometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Wideband Tympanometry
Study: NCT03894397

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical stimulation of the BNST
Description: Electrical stimulation of the BNST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the BNST
Description: Electrical stimulation of the BNST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the BNST
Description: Electrical stimulation of the BNST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the BNST
Description: Electrical stimulation of the BNST
Study: NCT01301898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1111_0.5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1111_1.0mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elaprase_0.5mg/kg
Study: NCT03568656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 500mg tablets plus prednisone/prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 40mg capsules/tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 300mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 150mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840mg/14ml concentrate for solution for infusion vials
Study: NCT02470000

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravascular laser irradiation of blood (ILIB)
Description: continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (ILIB)
Description: continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS over neck for 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS over neck for 15 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching exercise
Description: stretching exercise to the involved muscle for 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: stretching exercise to the involved muscle for 15 minutes.
Study: NCT01572987

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation(RFA) by HALO device.
Description: RFA or Surveillance every 2 months for 1 year.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection(EMR) by mucosectomy kit.
Description: EMR or surveillance every 2 months.
Study: NCT04027478

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FMD
Description: fasting mimicking diet
Study: NCT04001959

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride with Potassium Iodide
Description: Dry the tooth for 30 seconds with air jet and apply one drop of Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the treated surface, then wash.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride with Potassium Iodide
Description: Dry the tooth for 30 seconds with air jet and apply one drop of Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the treated surface, then wash.
Study: NCT03815318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation FVIII
Description: Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Study: NCT01912313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy
Study: NCT04388462

Intervention type: OTHER
Intervention: Finite element analysis
Description: Biomechanical study to describe micromotion

Intervention type: OTHER
Intervention: Finite element analysis
Description: Biomechanical study to describe micromotion

Intervention type: OTHER
Intervention: Finite element analysis
Description: Biomechanical study to describe micromotion
Study: NCT00527241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raices nuevas
Description: 8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
Study: NCT02921334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: switching between invasive and noninvasive ventilation
Description: As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
Study: NCT00933556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: 6 gms of powder formulation to be given once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill (placebo)
Description: placebo identical to the active product will be given
Study: NCT03844204

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal servo-controlled system
Description: All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal servo-controlled system
Description: All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
Study: NCT04075253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VO2 peak testing
Description: Exercise on treadmill starts with \~4km/h at 0% inclination before inclination is increased to 4% and speed kept unchanged. Inclination will then be increased with two percent approximately after each minute until exhaustion.
Study: NCT01014910

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous pulse oximetry monitoring
Description: Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pulse oximetry monitoring
Description: Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.